Novo Nordisk A/S reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was DKK 41,265 million compared to DKK 33,041 million a year ago. Net income was DKK 13,318 million compared to DKK 12,123 million a year ago. Basic earnings per share from continuing operations was DKK 5.87 compared to DKK 5.26 a year ago. Diluted earnings per share from continuing operations was DKK 5.86 compared to DKK 5.26 a year ago.
For the six months, sales was DKK 83,296 million compared to DKK 66,845 million a year ago. Net income was DKK 27,528 million compared to DKK 24,746 million a year ago. Basic earnings per share from continuing operations was DKK 12.11 compared to DKK 10.73 a year ago. Diluted earnings per share from continuing operations was DKK 12.08 compared to DKK 10.71 a year ago.